Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial

Next Previous
X
Search
Trial Profile

Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Cardiovascular disorders; Low cardiac output
  • Focus Therapeutic Use
  • Acronyms CHEETAH

    • Most Recent Events

    • 04 Apr 2022 Results of a subset analysis assessing the the safety of continuous mechanical aspiration using a novel monorail catheter system prior to PCI in a high thrombus burden STEMI presented at the 71st Annual Scientific Session of the American College of Cardiology
    • 21 Jul 2016 Status changed from recruiting to completed.
    • 01 Jul 2016 Trial design published in the American Heart Journal

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top